Argenx SE
ARGX
주식 순위
#446
argenx SE, a biotechnology company established in Amsterdam, the Netherlands,... argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
주가
$880.20
시가총액
$55.17B
변동 (1일)
6.61%
변동 (1년)
3.62%
국가
NL
거래 Argenx SE (ARGX)
카테고리
Healthcare
Argenx SE (ARGX)의 P/E 비율
October 2026 기준 P/E 비율 TTM: 30.33
Argenx SE의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 30.33입니다. 2023년 말 기준 P/E 비율은 -73.46였습니다.
Argenx SE의 P/E 비율 기록 (2010 ~ 2026)
매년 말 P/E 비율
| 연도 | P/E 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 30.33 | -39.77% |
| 2024 | 50.36 | -168.56% |
| 2023 | -73.46 | 157.20% |
| 2022 | -28.56 | -38.42% |
| 2021 | -46.38 | 156.77% |
| 2020 | -18.06 | -40.99% |
| 2019 | -30.60 | -23.89% |
| 2018 | -40.21 | 1.91% |
| 2017 | -39.45 | 195.63% |
| 2016 | -13.35 | 28.85% |
| 2015 | -10.36 | 8.55% |
| 2014 | -9.54 | -34.89% |
| 2013 | -14.65 | 51.49% |
| 2012 | -9.67 | -64.98% |
| 2011 | -27.63 | 0.00% |
| 2010 | 0.00 | 0.00% |
유사 기업 또는 경쟁사의 P/E 비율
| 회사 | P/E 비율 | P/E 비율 차이 | 국가 |
|---|---|---|---|
| 28.78 | -5.10% |
US
|
|
| -28.36 | -193.50% |
US
|
|
| -24.57 | -181.00% |
AU
|
|
| - | - |
CH
|
|
| 17.49 | -42.34% |
BE
|
P/E 비율 읽는 방법
P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.
P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.
양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.